Azithromycin 250 mg Tablets Should Not Be Split
Azithromycin 250 mg tablets are not designed to be split and should be administered as whole tablets. The FDA-approved formulation specifies these tablets as film-coated, oval, biconvex tablets without score lines, indicating they are intended for whole-tablet administration 1.
Key Considerations
Formulation Design
The azithromycin 250 mg tablets are film-coated formulations without score lines 1. Film-coated tablets are specifically manufactured to:
- Protect the drug from degradation
- Mask taste
- Control drug release
- Facilitate swallowing
Breaking the film coating compromises these protective features and may affect drug stability and absorption.
Dosing Flexibility Without Splitting
The FDA label demonstrates that appropriate dosing can be achieved without tablet splitting 1:
- Two 250 mg tablets are bioequivalent to a single 500 mg tablet when taken together
- Standard regimens use whole tablets: 500 mg (two 250 mg tablets) on day 1, followed by 250 mg (one tablet) daily on days 2-5
- Multiple tablet strengths are available (250 mg and 500 mg) to accommodate different dosing needs
Evidence Against Tablet Splitting
Research on tablet splitting reveals significant concerns 2:
- Weight and drug content uniformity frequently fall outside acceptable specifications when tablets are split
- Fragment and powder loss during splitting leads to dose variation
- Tablets without score lines show greater variability when split
While this study did not specifically test azithromycin, the principles apply to all film-coated tablets without score lines.
Clinical Recommendations
If a dose adjustment is needed:
- Use the liquid suspension formulation (available as 20 mg/mL or 40 mg/mL) for precise dose titration 3
- Consult with the prescriber to adjust the prescription to use whole tablets in appropriate combinations
- Consider alternative dosing schedules using whole tablets
Common pitfall: Attempting to split tablets to reduce costs or adjust doses without considering the impact on drug delivery and efficacy. This practice may result in subtherapeutic dosing or treatment failure, particularly for infections requiring precise antimicrobial concentrations 4.
The film-coated formulation without score lines is a clear indication from the manufacturer that these tablets should remain intact for optimal therapeutic effect.